SOURCE-LINKED STUDY SUMMARY
Immunometabolic effects of oral testosterone for castration-resistant prostate cancer in the ACROBAT trial.
Abstract summarizedQuality not appraised
- What was studied
- An ACROBAT substudy examined metabolic and immune changes during testosterone treatment.
- Who / model studied
- 10 patients with castration-resistant prostate cancer; longitudinal within-patient measurements.
- Studied dose & schedule
- High-dose oral testosterone undecanoate; exact dose, frequency and sampling duration were absent from the abstract.
- What the study found
- Polyamine-related metabolites increased; nonresponders had higher polyamine concentrations. Immune-cell frequencies did not significantly change. Associations with immunosuppressive cells were exploratory.
- Limitations & context
- Tiny disease-specific sample without a randomized untreated comparator described. Cannot establish healthy-user hypertrophy, cancer risk or a resistance mechanism. Abstract assessment; adverse-event counts unavailable.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1158/1541-7786.MCR-26-0573